Is Kyverna Therapeutics, Inc. (KYTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.7% / 30% | 59.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.7% / 33% | 59.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.7% / 33% | 93.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.7% / 33% | 59.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.7% / 33% | 93.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -70.8% | |
| Return on Assets (ROA) | -40.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$114M |
| Free Cash Flow | -$116M |
| Total Debt | $8M |
| Debt-to-Equity | 3.3 |
| Current Ratio | 5.2 |
| Total Assets | $305M |
Price & Trading
| Last Close | $8.03 |
| 50-Day MA | $8.31 |
| 200-Day MA | $6.32 |
| Avg Volume | 773K |
| Beta | 3.3 |
|
52-Week Range
$1.78
| |
About Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Kyverna Therapeutics, Inc. (KYTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Kyverna Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Kyverna Therapeutics, Inc.'s debt ratio?
Kyverna Therapeutics, Inc.'s debt ratio is 1.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.7%.
What are Kyverna Therapeutics, Inc.'s key financial metrics?
Kyverna Therapeutics, Inc. has a market capitalization of $472M. Return on equity stands at -70.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.